Abgenix


Public list: Pharma Startups (6570) Cancer Therapeutics (1180)

Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the platform to its strategic partners and licensing customers.

Abgenix aims to deliver fully human monoclonal antibodies for a range of disease targets, several of which are currently in clinical trials. The company leverages its XenoMouse technology platform to support product development, while offering the pl...Show all

Company (Acquired)

All investors data 32 Investors

Phone: 510-284-6500

Fax:

6701 Kaiser Drive

 Fremont, 94555
 California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Abgenix $246.6M Apr 1, 2006
Ribozyme Pharmaceuticals $0M Dec 24, 2020
ApoLife $0M Dec 24, 2020
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Abgenix Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 32 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Method for preparing monoclonal antibody Sep 28, 2005 Aug 07, 2012 Patent
Antibodies to cd40 and methods of treating cancer and enhancing immune responses Aug 26, 2005 Jul 21, 2009 Patent